Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy
Open Access
- 1 August 1995
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 72 (2) , 361-366
- https://doi.org/10.1038/bjc.1995.339
Abstract
The expression of epidermal growth factor receptor (EGFR), oestrogen receptor (ER) and progesterone receptor (PR) was assayed by a radioreceptor method in 117 primary ovarian cancers. EGFR was not significantly related to any of the clinicopathological parameters examined. In patients with stage II-IV disease who underwent second-look surgery after primary chemotherapy, a significant correlation between high EGFR levels and poor response to chemotherapy was demonstrated (P = 0.031). Moreover, post-operative residual tumour showed an independent role in predicting chemotherapy response (P = 0.0007) and EGFR status showed a borderline significance (P = 0.052) in the multivariate analysis. No correlation between steroid hormone receptors and clinicopathological parameters was observed. Whereas a significant relationship was shown between EGFR positivity and a shorter overall survival (OS) (P = 0.0022) and progression-free survival (PFS) (P = 0.0033), patient survival was not related to steroid hormone receptor status. Among the parameters tested only stage, ascites and EGFR status retained an independent prognostic value in the multivariate analysis.Keywords
This publication has 30 references indexed in Scilit:
- Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptorEuropean Journal Of Cancer, 1994
- A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine KinaseScience, 1994
- Significance of epidermal growth factor receptor expression in primary human endometrial cancerInternational Journal of Cancer, 1994
- The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot studyEuropean Journal Of Cancer, 1993
- Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-upInternational Journal of Gynecologic Cancer, 1993
- Expression of Epidermal Growth Factor Receptor in Normal Ovary and in Ovarian TumorsInternational Journal of Gynecological Pathology, 1992
- Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin.Journal of Clinical Investigation, 1990
- Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinomaBJOG: An International Journal of Obstetrics and Gynaecology, 1990
- Doxorubicin and Cyclophosphamide, Alternated with Bleomycin and Mitomycin C as a Second-Line Regimen in Advanced Ovarian Carcinoma Resistant to Cisplatin-Based ChemotherapyOncology, 1990
- Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomasGynecologic Oncology, 1988